troglitazone has been researched along with clofibrate in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, Y; Fujita, T; Hasegawa, K; Horikoshi, H; Kanai, T; Kurumada, T; Yoshioka, T | 1 |
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Lin, HR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Barrera, G; Briatore, F; Dianzani, MU; Ferretti, C; Laurora, S; Pizzimenti, S | 1 |
| Johnson, JH; McCarthy, KJ; Routh, RE | 1 |
| Baik, EJ; Kim, EJ; Kwon, KJ; Lee, SH; Moon, CH; Park, JY | 1 |
| Kobayashi, H; Minami, S; Saitoh, T; Shiraishi, S; Sugano, T; Wada, A; Yanagita, T; Yokoo, H | 1 |
| Barrera, G; Briatore, F; Dianzani, MU; Ferretti, C; Fraioli, A; Laurora, S; Maggio, M; Pizzimenti, S; Reffo, P | 1 |
| Chen, ZJ; Yang, LY; Yang, YN | 1 |
| Beauregard, C; Brandt, PC | 1 |
| Asai, M; Hashimoto, K; Iwasaki, Y; Kambayashi, M; Nishiyama, M; Taguchi, T; Takayasu, S; Tsugita, M; Yoshida, M | 1 |
2 review(s) available for troglitazone and clofibrate
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for troglitazone and clofibrate
| Article | Year |
|---|---|
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
Topics: Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Phenols; Rats; Structure-Activity Relationship | 1989 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists.
Topics: Diabetes Mellitus; Drugs, Chinese Herbal; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Lactones; Molecular Structure; Plants; PPAR alpha; Sesquiterpenes; Signal Transduction | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation.
Topics: Aldehydes; Cell Differentiation; Cell Division; Chromans; Clofibrate; Clofibric Acid; Drug Synergism; Fibric Acids; HL-60 Cells; Humans; Ligands; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; U937 Cells | 2002 |
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
Topics: Animals; Cells, Cultured; Chromans; Clofibrate; Collagen Type I; Extracellular Matrix Proteins; Glomerular Mesangium; Hyperglycemia; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.
Topics: Animals; Cell Culture Techniques; Cell Death; Chromans; Clofibrate; Cyclooxygenase 2; Dinoprostone; Electrophoretic Mobility Shift Assay; Escherichia coli; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Lipopolysaccharides; Mice; Mice, Inbred ICR; Neurons; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxisome Proliferators; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Distinct effects of ketone bodies on down-regulation of cell surface insulin receptor and insulin receptor substrate-1 phosphorylation in adrenal chromaffin cells.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adrenal Glands; Animals; Cattle; Chromaffin Cells; Chromans; Clofibrate; Culture Media; Down-Regulation; Epoprostenol; Insulin; Insulin Receptor Substrate Proteins; Iodine Radioisotopes; Ketone Bodies; Membrane Proteins; Phosphoproteins; Phosphorylation; Receptor, Insulin; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Tyrosine | 2003 |
Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Chromans; Clofibrate; Clofibric Acid; Fibric Acids; Gene Expression; HL-60 Cells; Humans; Ligands; Oncogenes; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
[The effect of peroxisome proliferator-activated receptor alpha and gamma ligands on free fatty acid-induced INS-1 cell impairment].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Cell Line, Tumor; Chromans; Clofibrate; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulinoma; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells.
Topics: Animals; Cell Line, Transformed; Chromans; Clofibrate; Dexamethasone; Gene Expression; Humans; Interleukin-1; Lacrimal Apparatus; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; PPAR alpha; PPAR gamma; Pterins; Pyrimidines; Rabbits; Thiazolidinediones; Troglitazone | 2003 |
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Anticholesteremic Agents; Base Sequence; Cell Line; Chromans; Clofibrate; Cortisone; Cushing Syndrome; Dexamethasone; Gene Expression Regulation, Enzymologic; Glucocorticoids; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Interleukin-1beta; Liver; Metabolic Syndrome; Metformin; Molecular Sequence Data; Receptors, Glucocorticoid; Thiazolidinediones; Transcription Factor AP-1; Troglitazone; Tumor Necrosis Factor-alpha | 2008 |